CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...